Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
national top stories
8
×
boston blog main
boston top stories
biotech
clinical trials
new york blog main
boston
new york top stories
san diego blog main
san francisco blog main
deals
drugs
san diego top stories
san francisco top stories
startups
akcea therapeutics
atlas venture
cancer
gene therapy
inotersen
new york
patisiran
regeneron pharmaceuticals
rna interference
tafamidis
wisconsin blog main
wisconsin top stories
accelerator
adeno-associated virus
airbnb
alexion pharmaceuticals
allosteric
alnylam pharmaceutials
alnylam pharmaceuticals
amarin
amazon web services (aws)
anylam pharmaceuticals
arrowhead pharmaceuticals
What
ago
8
×
medicines
therapeutics
years
alnylam
big
biotechs
companies
disease
drug
fda
genetic
long
patients
rare
rna
abandoning
abuzz
adding
address
adds
admits
aiming
akcea
allosteric
amarin
amyloidosis
approve
approved
attr
available
awaits
baggage
balance
battle
biological
build
classes
clinic
clinical
Language
unset
Current search:
ago
×
" national top stories "
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Deeper Dive: Amarin Fish-Oil Study Gives Eager Doctors More to Ponder
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision